Remarkably, the “Triplet” therapy combining Ad-p53 with selective CD122/CD132 agonists and immune checkpoint blockade resulted in the complete tumor remissions and potentially curative outcomes that significantly surpassed the efficacy of all other doublet and monotherapies tested, which did not generate complete responses nor extended survivals. Here, IL2RB is linked to neoplasm.